COT Well-positioned with Adaptable Technology

NY, NY—(7/15/2013) – Critical Outcome Technologies’ CEO Dr. Wayne Danter took time to update the investment community on COT’s recent news and progress.  During his in-depth interview with The Wall Street Analyst, Dr. Danter discusses the first commercial project from their core technology, COTI-2.  He believes it will be in phase 1 by the end of the year and foresees the trends in the sector going towards gene therapies.  In addition, he compares the way people will be able to access their technologies to the way consumers access iTunes, via a web portal.  Dr. Danter also talks about his background and experience as well as management’s key goal of partnering their lead asset and rolling out the CHEFIRM application. Dr. Danter adds that COT is not a one-trick pony: their technology allows them to pursue multiple projects simultaneously, which he feels sets them apart from other bio-tech companies.

CLICK HERE FOR FULL INTERVIEW

For More Information Please Contact:

Critical Outcome Technologies Inc. Dr. Wayne Danter
President & CEO Tel:519‐858‐5157

Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416‐500‐8061
Email: trevor@heislercommunications.com

Email: wdanter@criticaloutcome.com
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

About The Wall Street Analyzer 1646 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.